Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX

Boxer Capital Management LLC bought a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 125,000 shares of the company’s stock, valued at approximately $1,589,000. Avalo Therapeutics makes up about 0.5% of Boxer Capital Management LLC’s holdings, making the stock its 27th largest position. Boxer Capital Management LLC owned about 0.69% of Avalo Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in AVTX. Caligan Partners LP acquired a new position in Avalo Therapeutics during the third quarter worth $10,592,000. Balyasny Asset Management L.P. acquired a new stake in shares of Avalo Therapeutics in the third quarter valued at about $10,390,000. Vanguard Group Inc. grew its position in shares of Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after purchasing an additional 525,696 shares during the period. Bank of America Corp DE increased its stake in shares of Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after purchasing an additional 400,898 shares in the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after purchasing an additional 382,300 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Avalo Therapeutics in a research note on Thursday, January 15th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim started coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Price Performance

AVTX opened at $15.80 on Friday. The firm has a market capitalization of $292.46 million, a price-to-earnings ratio of -2.95 and a beta of 0.84. The company’s 50 day simple moving average is $15.89 and its two-hundred day simple moving average is $15.52. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $20.72.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.